ROPIVACAINE MESYLATE

Name	Ropivacaine mesylate
Synonyms	ROPIVACAINE MESYLATE Ropivacaine mesylate S-Ropivacaine mesylate (S)-Ropivacaine Mesilate Ropivacaine Mesylate API Ropivacaine Mesylate Injection TIANFUCHEM--854056-07-8--Ropivacaine mesylate in stock (S)-N-(2,6-Dimethylphenyl)-1-propylpiperidine-2-carboxamidemethanesulfonate (2S)-N-(2,6-Dimethylphenyl)-1-propyl-2-piperidinecarboxamide monomethanesulfonate Ropivacaine mesylate (2S)-N-(2,6-Dimethylphenyl)-1-propyl-2-piperidinecarboxamide monomethanesulfonate
CAS	854056-07-8
EINECS	264-407-7
InChI	InChI=1/C17H26N2O.CH4O3S/c1-4-11-19-12-6-5-10-15(19)17(20)18-16-13(2)8-7-9-14(16)3;1-5(2,3)4/h7-9,15H,4-6,10-12H2,1-3H3,(H,18,20);1H3,(H,2,3,4)/t15-;/m0./s1

Molecular Formula	C18H30N2O4S
Molar Mass	370.51
In vivo study	Epidural administration of Ropivacaine mesylate effectively blocks neuropathic pain (both mechanical allodynia and heat hyperalgesia) without induction of analgesic tolerance and significantly delays the development of neuropathic pain produced by peripheral nerve injury. Ropivacaine mesylate inhibits pressure-induced increases in filtration coefficient (Kf) without affecting pulmonary artery pressure (Ppa), pulmonary capillary pressures (Ppc), and zonal characteristics (ZC). Ropivacaine mesylate prevents pressure-induced lung edema and associated hyperpermeability as evidence by maintaining PaO2, lung wet-to-dry ratio and plasma volume in levels similar to sham rats. Ropivacaine mesylate inhibits pressure-induced NO production as evidenced by decreased lung nitro-tyrosine content when compared to hypertensive lungs. Animal Model: Adult Sprague-Dawley rats (300-400g) Dosage: 1 μM Administration: Infusion (added to the perfusate reservoir) Result: Attenuated pressure-dependent increases in filtration coefficient (K f ).

View History